Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: The impact on protein structure, dynamics, and stability

Biophysical Journal

Volumn 96, Issue 3, 2009, Pages 858-874

  Dixit, Anshuman ^a   Torkamani, Ali ^b   Schork, Nicholas J ^b   Verkhivker, Gennady ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE; PROTEIN RET; SCATTER FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; MET PROTEIN, HUMAN; MUTANT PROTEIN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR;

ARTICLE; CANCER GENETICS; CIRCULAR DICHROISM; DIFFERENTIAL SCANNING CALORIMETRY; ENTHALPY; ENTROPY; ENZYME STRUCTURE; GENE MUTATION; GENETIC CONSERVATION; HUMAN; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; MUTANT; ONCOGENE; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTEIN STRUCTURE; THERMODYNAMICS; WILD TYPE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; NEOPLASM; NUCLEOTIDE SEQUENCE;

COMPUTER SIMULATION; CONSERVED SEQUENCE; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; MODELS, MOLECULAR; MUTANT PROTEINS; MUTATION; NEOPLASMS; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTORS, GROWTH FACTOR; THERMODYNAMICS;

EID: 61549094352     PISSN: 00063495     EISSN: 15420086     Source Type: Journal    
DOI: 10.1016/j.bpj.2008.10.041     Document Type: Article

References (107)

1. Hanahan, D., and R. A. Weinberg. 2000. The hallmarks of cancer. Cell. 100:57-70.
2. Hahn, W. C., and R. A. Weinberg. 2002. Modeling the molecular circuitry of cancer. Nat. Rev. Cancer. 2:331-341.
3. Davies, H., G. R. Bignell, C. Cox, P. Stephens, S. Edkins, et al. 2002. Mutations of the BRAF gene in human cancer. Nature. 417:949-954.
4. Bardelli, A., D. W. Parsons, N. Silliman, J. Ptak, S. Szabo, et al. 2003. Mutational analysis of the tyrosine kinome in colorectal cancers. Science. 300:949.
5. Samuels, Y., Z. Wang, A. Bardelli, N. Silliman, J. Ptak, et al. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science. 304:554.
6. Wang, Z., D. Shen, D. W. Parsons, A. Bardelli, J. Sager, et al. 2004. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science. 304:1164-1166.
7. Futreal, P. A., L. Coin, M. Marshall, T. Down, T. Hubbard, et al. 2004. A census of human cancer genes. Nat. Rev. Cancer. 4:177-183.
8. Thomas, R. K., A. C. Baker, R. M. Debiasi, W. Winckler, T. Laframboise, et al. 2007. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39:347-351.
9. Hanks, S. K., and T. Hunter. 1995. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9:576-596.
10. Hunter, T. 2000. Signaling-2000 and beyond. Cell. 100:113-127.
11. Manning, G., D. B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam. 2002. The protein kinase complement of the human genome. Science. 298:1912-1934.
12. Scheeff, E. D., and P. E. Bourne. 2005. Structural evolution of the protein kinase-like superfamily. PLoS Comput Biol. 1:e49.
13. Kannan, N., S. S. Taylor, Y. Zhai, J. C. Venter, and G. Manning. 2007. Structural and functional diversity of the microbial kinome. PLoS Biol. 5:e17.
14. Knighton, D. R., J. H. Zheng, L. F. T. Eyck, V. A. Ashford, N. H. Xuong, et al. 1991. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science. 253:407-414.
15. Knighton, D. R., J. H. Zheng, L. F. T. Eyck, N. H. Xuong, S. S. Taylor, et al. 1991. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science. 253:414-420.
16. Johnson, L. N., M. E. Noble, and D. J. Owen. 1996. Active and inactive protein kinases: structural basis for regulation. Cell. 85:149-158.
17. Huse, M., and J. Kuriyan. 2002. The conformational plasticity of protein kinases. Cell. 109:275-282.
18. Nolen, B., S. Taylor, and G. Ghosh. 2004. Regulation of protein kinases; controlling activity through activation segment conformation. Mol. Cell. 15:661-675.
19. Stephens, P., S. Edkins, H. Davies, C. Greenman, C. Cox, et al. 2005. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat. Genet. 37:590-592.
20. Sjoblom, T., S. Jones, L. D. Wood, D. W. Parsons, J. Lin, et al. 2006. The consensus coding sequences of human breast and colorectal cancers. Science. 314:268-274.
21. Wood, L. D., D. W. Parsons, S. Jones, J. Lin, T. Sjoblom, et al. 2007. The genomic landscapes of human breast and colorectal cancers. Science. 318:1108-1113.
22. Greenman, C., P. Stephens, R. Smith, G. L. Dalgliesh, C. Hunter, et al. 2007. Patterns of somatic mutation in human cancer genomes. Nature. 446:153-158.
23. Sharma, S. V., and J. Settleman. 2007. Oncogene addiction: setting the stageformolecularlytargetedcancertherapy. GenesDev. 21:3214-3231.
24. Torkamani, A., and N. J. Schork. 2007. Accurate prediction of deleterious protein kinase polymorphisms. Bioinformatics. 23:2918-2925.
25. Torkamani, A., and N. J. Schork. 2008. Prediction of cancer driver mutations in protein kinases. Cancer Res. 68:1675-1682.
26. Torkamani, A., N. Kannan, S. S. Taylor, and N. J. Schork. 2008. Congenital disease SNPs target lineage specific structural elements in protein kinases. Proc. Natl. Acad. Sci. USA. 105:9011-9016.
27. Lynch, T. J., D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350:2129-2139.
28. Paez, J. G., P. A. Janne, J. C. Lee, S. Tracy, H. Greulich, et al. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497-1500.
29. Pao, W., V. Miller, M. Zakowski, J. Doherty, K. Politi, et al. 2004. EGF receptor gene mutations are common in lung cancers from ''never smokers'' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA. 101:13306-13311.
30. Greulich, H., T. -H. Chen, W. Feng, P. A. Janne, J. V. Alvarez, et al. 2005. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2:e313.
31. Zhang, X., J. Gureasko, K. Shen, P. A. Cole, and J. Kuriyan. 2006. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell. 125:1137-1149.
32. Yun, C. -H., T. J. Boggon, Y. Li, M. S. Woo, H. Greulich, et al. 2007. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 11:217-227.
33. Yun, C. -H., K. E. Mengwasser, A. V. Toms, M. S. Woo, H. Greulich, et al. 2008. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. USA. 105:2070-2075.
34. Kumar, A., E. T. Petri, B. Halmos, and T. J. Boggon. 2008. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J. Clin. Oncol. 26:1742-1751.
35. Modugno, M., E. Casale, C. Soncini, P. Rosettani, R. Colombo, et al. 2007. Crystal structure of the T315I AbI mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res. 67:7987-7990.
36. Zhou, T., L. Parillon, F. Li, Y. Wang, J. Keats, et al. 2007. Crystal structure of the T315I mutant of AbI kinase. Chem. Biol. Drug Des. 70:171-181.
37. Wong, C. F. 2008. Flexible ligand-flexible protein docking in protein kinase systems. Biochim. Biophys. Acta. 1784:244-251.
38. Cavasotto, C. N., and R. A. Abagyan. 2004. Protein flexibility in ligand docking and virtual screening to protein kinases. J. Mol. Biol. 337:209-225.
39. Rockey, W. M., and A. H. Elcock. 2006. Rapid computational identification of the targets of protein kinase inhibitors. Curr. Opin. Drug Discov. Devel. 9:326-331.
40. Young, M. A., S. Gonfloni, G. Superti-Furga, B. Roux, and J. Kuriyan. 2001. Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell. 105:115-126.
41. Liu, B., B. Bernard, and J. H. Wu. 2006. Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations. Proteins. 65:331-346.
42. Zou, J., Y. -D. Wang, F. -X. Ma, M. -L. Xiang, B. Shi, et al. 2008. Detailed conformational dynamics of juxtamembrane region and activation loop in c-Kit kinase activation process. Proteins. 72:323-332.
43. Pricl, S., M. Fermeglia, M. Ferrone, and E. Tamborini. 2005. T315I- mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study. Mol. Cancer Ther. 4:1167-1174.
44. Lee, T. -S., S. J. Potts, H. Kantarjian, J. Cortes, F. Giles, et al. 2008. Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer. 112:1744-1753.
45. Verkhivker, G. M. 2006. Imprint of evolutionary conservation and protein structure variation on the binding function of protein tyrosine kinases. Bioinformatics. 22:1846-1854.
46. Verkhivker, G. M. 2007. Computational proteomics of biomolecular interactions in the sequence and structure space ofthe tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity. Proteins. 66:912-929.
47. Verkhivker, G. M. 2007. In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures. Biopolymers. 85:333-348.
48. Verkhivker, G. M. 2007. Exploring sequence-structure relationships in the tyrosine kinome space: functional classification of the binding specificity mechanisms for cancer therapeutics. Bioinformatics. 23:1919-1926.
49. Stenberg, K. A., P. T. Riikonen, and M. Vihinen. 1999. KinMutBase, a database of human disease-causing protein kinase mutations. Nucleic Acids Res. 27:362-364.
50. Stenberg, K. A., P. T. Riikonen, and M. Vihinen. 2000. KinMutBase, a database of human disease-causing protein kinase mutations. Nucleic Acids Res. 28:369-371.
51. Santoro, M., R. M. Melillo, F. Carlomagno, A. Fusco, and G. Vecchio. 2002. Molecular mechanisms of RET activation in human cancer. Ann. N. Y. Acad. Sci. 963:116-121.
52. Santoro, M., R. M. Melillo, F. Carlomagno, G. Vecchio, and A. Fusco. 2004. Minireview: RET: normal and abnormal functions. Endocrinology. 145:5448-5451.
53. Cranston, A. N., C. Carniti, K. Oakhill, E. Radzio-Andzelm, E. A. Stone, et al. 2006. RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cancer Res. 66:10179-10187.
54. Gujral, T. S., V. K. Singh, Z. Jia, and L. M. Mulligan. 2006. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B. Cancer Res. 66:10741-10749.
55. Gujral, T. S., and L. M. Mulligan. 2006. Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2. Ann. N. Y. Acad. Sci. 1073:234-240.
56. Lai, A. Z., T. S. Gujral, and L. M. Mulligan. 2007. RET signaling in endocrine tumors: delving deeper into molecular mechanisms. Endocr. Pathol. 18:57-67.
57. Maritano, D., P. Accornero, N. Bonifaci, and C. Ponzetto. 2000. Two mutations affecting conserved residues in the Met receptor operate via different mechanisms. Oncogene. 19:1354-1361.
58. Nakaigawa, N., G. Weirich, L. Schmidt, and B. Zbar. 2000. Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant- negative Src. Oncogene. 19:2996-3002.
59. Morotti, A., S. Mila, P. Accornero, E. Tagliabue, and C. Ponzetto. 2002. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene. 21:4885-4893.
60. Berthou, S., D. M. Aebersold, L. S. Schmidt, D. Stroka, C. Heigl, et al. 2004. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene. 23:5387-5393.
61. Miller, M., K. Ginalski, B. Lesyng, N. Nakaigawa, L. Schmidt, et al. 2001. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. Proteins. 44:32-43.
62. Knowles, P. P., J. Murray-Rust, S. Kjaer, R. P. Scott, S. Hanrahan, et al. 2006. Structure and chemical inhibition of the RET tyrosine kinase domain. J. Biol. Chem. 281:33577-33587.
63. Stamos, J., M. X. Sliwkowski, and C. Eigenbrot. 2002. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277:46265-46272.
64. Plaza-Menacho, I., L. Mologni, E. Sala, C. Gambacorti-Passerini, A. I. Magee, et al. 2007. Sorafenib functions to potently suppress RET tyro- sine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J. Biol. Chem. 282:29230-29240.
65. Schiering, N., S. Knapp, M. Marconi, M. M. Flocco, J. Cui, et al. 2003. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc. Natl. Acad. Sci. USA. 100:12654-12659.
66. Carlomagno, F., D. Vitagliano, T. Guida, M. Napolitano, G. Vecchio, et al. 2002. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res. 62:1077-1082.
67. Carlomagno, F., T. Guida, S. Anaganti, G. Vecchio, A. Fusco, et al. 2004. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene. 23:6056-6063.
68. Carlomagno, F., D. Vitagliano, T. Guida, F. Ciardiello, G. Tortora, et al. 2002. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 62:7284-7290.
69. Carlomagno, F., D. Vitagliano, T. Guida, F. Basolo, M. D. Castellone, et al. 2003. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4- d]pyrimidine (PP2). J. Clin. Endocrinol. Metab. 88:1897-1902.
70. Marti-Renom, M. A., A. C. Stuart, A. Fiser, R. Sanchez, F. Melo, et al. 2000. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 29:291-325.
71. Fiser, A., R. K. Do, and A. Sali. 2000. Modeling of loops in protein structures. Protein Sci. 9:1753-1773.
72. Canutescu, A. A., A. A. Shelenkov, and R. L. J. Dunbrack. 2003. A graph-theory algorithm for rapid protein side-chain prediction. Protein Sci. 12:2001-2014.
73. Phillips, J. C., R. Braun, W. Wang, J. Gumbart, E. Tajkhorshid, et al. 2005. Scalable molecular dynamics with NAMD. J. Comput. Chem. 26:1781-1802.
74. Humphrey, W., A. Dalke, and K. Schulten. 1996. VMD: visual molecular dynamics. J. Mol. Graph. 14:33-38.
75. Eargle, J., D. Wright, and Z. Luthey-Schulten. 2006. Multiple alignment of protein structures and sequences for VMD. Bioinformatics. 22:504-506.
76. Essmann, U., L. Perera, M. L. Berkowitz, T. Darden, H. Lee, et al. 1995. A smooth particle mesh Ewald method. J. Chem. Phys. 103:8577-8593.
77. Verkhivker, G. M., D. Bouzida, D. K. Gehlhaar, P. A. Rejto, S. Arthurs, et al. 2000. Deciphering common failures in molecular docking of ligand-protein complexes. J. Comput. Aided Mol. Des. 14:731-751.
78. Wang, J., R. M. Wolf, J. W. Caldwell, P. A. Kollman, and D. A. Case. 2004. Development and testing of a general AMBER force field. J. Comput. Chem. 25:1157-1174.
79. Srinivasan, J., J. Miller, P. A. Kollman, and D. A. Case. 1998. Continuum solvent studies of the stability of RNA hairpin loops and helices. J. Biomol. Struct. Dyn. 16:671-682.
80. Kollman, P. A., I. Massova, C. Reyes, B. Kuhn, S. Huo, et al. 2000. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 33:889-897.
81. Verkhivker, G. M., D. Bouzida, D. K. Gehlhaar, P. A. Rejto, S. T. Freer, et al. 2002. Monte Carlo simulations of the peptide recognition at the consensus binding site of the constant fragment of human immu- noglobulin G: the energy landscape analysis of a hot spot at the intermolecular interface. Proteins. 48:539-557.
82. Verkhivker, G. M., D. Bouzida, D. K. Gehlhaar, P. A. Rejto, S. T. Freer, et al. 2003. Computational detection of the binding-site hot spot at the remodeled human growth hormone-receptor interface. Proteins. 53:201-219.
83. Verkhivker, G. M. 2004. Computational analysis of ligand binding dynamics at the intermolecular hot spots with the aid of simulated tempering and binding free energy calculations. J. Mol. Graph. Model. 22:335-348.
84. Gilson, M. K., and H. -X. Zhou. 2007. Calculation of protein-ligand binding affinities. Annu. Rev. Biophys. Biomol. Struct. 36:21-42.
85. Parthiban, V., M. M. Gromiha, and D. Schomburg. 2006. CUPSAT: prediction of protein stability upon point mutations. Nucleic Acids Res. 34:W239-W242.
86. Parthiban, V., M. M. Gromiha, M. Abhinandan, and D. Schomburg. 2007. Computational modeling of protein mutant stability: analysis and optimization of statistical potentials and structural features reveal insights into prediction model development. BMC Struct. Biol. 7:54.
87. Schymkowitz, J., J. Borg, F. Stricher, R. Nys, F. Rousseau, et al. 2005. The FoldX web server: an online force field. Nucleic Acids Res. 33:W382-W388.
88. Guerois, R., J. E. Nielsen, and L. Serrano. 2002. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J. Mol. Biol. 320:369-387.
89. Liu, X., Q. C. Vega, R. A. Decker, A. Pandey, C. A. Worby, et al. 1996. Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities. J. Biol. Chem. 271:5309-5312.
90. Yuan, Z. -L., Y. -J. Guan, L. Wang, W. Wei, A. B. Kane, et al. 2004. Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells. Mol. Cell. Biol. 24:9390-9400.
91. Durney, M. A., R. W. Wechselberger, C. G. Kalodimos, R. Kaptein, C. E. Vorgias, et al. 2004. An alternate conformation of the hyper- thermostable HU protein from Thermotoga maritima has unexpectedly high flexibility. FEBS Lett. 563:49-54.
92. LeMaster, D. M., J. Tang, D. I. Paredes, and G. Hernandez. 2005. Enhanced thermal stability achieved without increased conformational rigidity at physiological temperatures: spatial propagation of differential flexibility in rubredoxin hybrids. Proteins. 61:608-616.
93. Bishop, S. M., J. B. Ross, and R. A. Kohanski. 1999. Autophosphorylation dependent destabilization of the insulin receptor kinase domain: tryptophan-1175 reports changes in the catalytic cleft. Biochemistry. 38:3079-3089.
94. Ablooglu, A. J., and R. A. Kohanski. 2001. Activation of the insulin receptor's kinase domain changes the rate-determining step of substrate phosphorylation. Biochemistry. 40:504-513.
95. Wang, W., A. Marimuthu, J. Tsai, A. Kumar, H. I. Krupka, et al. 2006. Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc. Natl. Acad. Sci. USA. 103:3563-3568.
96. van derVaart, A., and M. Karplus. 2005. Simulation of conformational transitions by the restricted perturbation-targeted molecular dynamics method. J. Chem. Phys. 122:114903.
97. Jeffers, M., L. Schmidt, N. Nakaigawa, C. P. Webb, G. Weirich, et al. 1997. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA. 94:11445-11450.
98. Schmidt, L., K. Junker, N. Nakaigawa, T. Kinjerski, G. Weirich, et al. 1999. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 18:2343-2350.
99. Iwashita, T., K. Kurokawa, S. Qiao, H. Murakami, N. Asai, et al. 2001. Functional analysis of RET with Hirschsprung mutations affecting its kinase domain. Gastroenterology. 121:24-33.
100. Yue, P., Z. Li, and J. Moult. 2005. Loss of protein structure stability as a major causative factor in monogenic disease. J. Mol. Biol. 353:459-473.
101. Maguid, S., S. Fernandez-Alberti, G. Parisi, and J. Echave. 2006. Evolutionary conservation of protein backbone flexibility. J. Mol. Evol. 63:448-457.
102. Maguid, S., S. Fernandez-Alberti, L. Ferrelli, and J. Echave. 2005. Exploring the common dynamics of homologous proteins. Application to the globin family. Biophys. J. 89:3-13.
103. Shoemaker, B. A., J. J. Portman, and P. G. Wolynes. 2000. Speeding molecular recognition by using the folding funnel: the fly-casting mechanism. Proc. Natl. Acad. Sci. USA. 97:8868-8873.
104. Levy, Y., P. G. Wolynes, andJ. N. Onuchic. 2004. Proteintopologydeter- mines binding mechanism. Proc. Natl. Acad. Sci. USA. 101:511-516.
105. Tsai, C. J., B. Ma, and R. Nussinov. 1999. Folding and binding cascades: shifts in energy landscapes. Proc. Natl. Acad. Sci. USA. 96:9970-9972.
106. Verkhivker, G. M., D. Bouzida, D. K. Gehlhaar, P. A. Rejto, S. T. Freer, et al. 2002. Complexity and simplicity of ligand-macromolecule interactions: the energy landscape perspective. Curr. Opin. Struct. Biol. 12:197-203.
107. Thorpe, I. F., and C. L. Brooks, III. 2007. Molecular evolution of affinity and flexibility in the immune system. Proc. Natl. Acad. Sci. USA. 104:8821-8826.